drugset

drugset / Trial / NCT04974684

DOT HeartMate 3 Study

NCT04974684 ↗

Completed 45 enrolled Institute for Clinical and Experimental Medicine

RandomizedParallel-groupOpen-labelOther

Summary

A prospective, single-center, randomized controlled trial of the feasibility and safety of apixaban in HeartMate 3 patients.

Timeline

Start: 2022-04-01
Primary completion: 2024-03-01
Completion: 2024-03-01

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Apixaban	Small molecule	5 mg	Oral

Indications